After raising €2M in its successful IPO, ExpreS2ion Biotech starts trading on Nasdaq First North in Stockholm – a real milestone for this industrial spin-out.
Expres2ion Biotech started out in 2010, as a spin-out of a Danish company focused on human antibodies, Affitech.
Affitech itself has had a convoluted path. It was initially Norwegian, then merging with the Danish vaccine-focused Pharmexa (which researched a universal cancer vaccine, for example). And now its programs are, it seems, being managed through its UK subsidiary (Actigen).
Based near Copenhagen, Expres2ion took over a platform for vaccine production of its parent company. The technology was a cell expression system based on the Schneider 2 (S2) cell lines of the common fruit fly (Drosophila melanogaster).
In 2016, the new ExpreS2ion Biotech Holding AB was founded in Sweden, having the Danish Biotech as a subsidiary. It’s through this holding company that Expres2ion has now made it to the markets,